Anti-Mouse Osteoprotegerin - Biotin
| Code | Size | Price |
|---|
| LEI-O132-50ug | 50 ug | £739.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Caprine (Goat)
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Shipping:
Ambient
Storage:
The lyophilized biotinylated antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for up to twelve months from date of receipt. The reconstituted biotin conjugate can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted conjugate aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.
Further Information
Conjugate/Tag/Label:
Biotin
Format:
This biotinylated antigen affinity purified polyclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 containing 50 ug of bovine serum albumin per ug of antibody with no calcium, magnesium, or preservatives present.
Formulation:
This biotinylated antigen affinity purified polyclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 containing 50 ug of bovine serum albumin per ug of antibody with no calcium, magnesium, or preservatives present.
Immunogen:
Purified Recombinant Mouse OPG (Accession # Q6PI12)
Long Description:
Osteoprotegerin (OPG), also known as osteoclastogenesis inhibitory factor (OCIF) is a cytokine, which can inhibit osteoclast differentiation, activity, and survival.1 It is a member of the tumor necrosis factor (TNF) receptor superfamily.2 OPG may provide a pharmacological tool for osteoporotic and erosive bone disorders.3
NCBI Gene:
18383
Target:
Osteoprotegerin
References
1. Kurihara, H. et al. (2002) Cytokine 18: 1332. Schoppet, M. et al. (1980) Arteriosclerosis, Thrombosis, & Vascular Biol. 22: 5493. Dunstan, CR. et al. (2001) J Bone Miner Res. 16: 348
Related Products
| Product Name | Product Code | Supplier | Recombinant Human Osteoprotegerin (OPG) | LEI-O102 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Human Osteoprotegerin | LEI-O104 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human Osteoprotegerin - Biotin | LEI-O105 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Mouse Osteoprotegerin | LEI-O122 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse Osteoprotegerin | LEI-O125 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse Osteoprotegerin (Clone 110517) | LEI-O127 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human Osteoprotegerin (Clone 69146) | LEI-O129 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Human Osteoprotegerin | LEI-O137 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||